Community Health Network

Indianapolis, Indiana 46256

20 studies enrolling now · 47 studies all time

What they study most

ATC, Acinar Cell Carcinoma, Acute Myeloid Leukemia, Advanced Breast Cancer, Advanced Cancer, Advanced Solid Tumor, Advanced Unresectable Solid Tumors, Alzheimer Disease, Atherosclerotic Cardiovascular Disease, BRAF-mutated Tumors, Biliary Tract Neoplasms, Breast Cancer

Studies at this site

• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread — Recruiting now
• Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension — Recruiting now
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• A Study of VIRTUGUIDE System and DePuy Synthes Lapidus Implant in Participants Undergoing Lapidus Procedure — Recruiting now
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — Recruiting now
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer — Recruiting now
• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers — Recruiting now
• Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies — Recruiting now
• A Study of LY4175408 in Participants With Advanced Cancer — Recruiting now
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC — Recruiting now
• The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR — Recruiting now
• A Study of VET3-TGI in Patients With Solid Tumors — Recruiting now
• GEMINI-NSCLC: NSCLC Biomarker Study — Recruiting now
• I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms — Recruiting now
• A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer — Recruiting now
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer — Recruiting now
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — Recruiting now
• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease — Enrolling by invitation
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies — Running, not enrolling
• Umbrella Study for Analysis of Data Related to Patients With Cancer — Completed
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) — Running, not enrolling
• S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP — Running, not enrolling
• LOWER: Lomitapide Observational Worldwide Evaluation Registry — Completed
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis — Completed
• Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — Running, not enrolling
• A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma — Running, not enrolling
• Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers — Stopped early
• A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension — Running, not enrolling
• A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors — Completed
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors — Stopped early
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression — Completed
• A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors — Completed
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy — Running, not enrolling
• A Study of SEA-CD40 Given With Other Drugs in Cancers — Completed
• Telephone Support for Metastatic Breast Cancer Patients — Completed
• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Running, not enrolling
• Multiple Cardiac Sensors for the Management of Heart Failure — Completed
• Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer — Stopped early
• Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer — Completed
• Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix) — Completed
• informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia — Completed
• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) — Stopped early
• CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) — Status unconfirmed
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer — Withdrawn before enrolling